(Stroke. 1995;26:1665-1669.)
© 1995 American Heart Association, Inc.
Articles |
From the Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pa.
Correspondence to Xinkang Wang, PhD, Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, 709 Swedeland Rd, PO Box 1539, UW2511, King of Prussia, PA 19406.
| Abstract |
|---|
|
|
|---|
Methods Northern blot analysis with the use of poly(A) RNA isolated from the ischemic and nonischemic rat cortex at 2 and 12 hours after permanent occlusion of the middle cerebral artery (PMCAO) was used to examine ELAM-1 mRNA expression. The temporal expression profile of ELAM-1 mRNA in the ischemic cortex was further evaluated with the use of a quantitative reverse transcription and polymerase chain reaction technique.
Results A very low level of ELAM-1 mRNA was detected in the sham-operated cortex or in the nonischemic cortex. The expression of ELAM-1 mRNA in the focal ischemic cortex was significantly induced by PMCAO, reaching a peak level at 12 hours (6.9-fold increase compared with sham surgery cortical samples, P<.01) and remained elevated for up to 2 days (3.3-fold increase, P<.01) after PMCAO.
Conclusions The demonstration of upregulated ELAM-1 mRNA expression after focal stroke suggests that ELAM-1 may play an important role in leukocyte infiltration into the ischemic brain and that ELAM-1 may provide a potential therapeutic target in ischemic stroke. However, the demonstration of translated ELAM-1 and its cellular localization in the ischemic tissue is required when specific antibodies become available.
Key Words: cerebral ischemia, focal endothelial leukocytes rats
| Introduction |
|---|
|
|
|---|
ELAM-1 is a single-chain glycoprotein belonging to the
selectin family. The expression of ELAM-1 has been found exclusively in vascular endothelial cells
after stimulation with inflammatory cytokines
(eg, IL-1 and TNF-
) and bacterial
endotoxin.5 6 12 Intravital microscopic studies have
revealed that ELAM-1 mediates leukocyte rolling in microvessels rather
than firm adhesion.13 However, rolling leukocytes
frequently lead to firm adhesion to the endothelial
cells in inflamed tissue.13 The ligand for ELAM-1 on
leukocytes has been identified as the blood group antigen sialyl-Lewis
x.6 Since TNF-
and IL-1ß are upregulated in the
ischemic cortex after PMCAO14 15 and/or MCAO with
reperfusion16 and increased infiltration of PMNs into the
focal ischemic tissue is observed under these
conditions,1 2 3 4 we postulated that ELAM-1 is also induced
in response to this ischemic brain injury. In the present
report we describe the use of both Northern analysis and a
sensitive quantitative RT-PCR technique to demonstrate that ELAM-1 mRNA
expression increases in ischemic cortex after PMCAO in the
rat.
| Materials and Methods |
|---|
|
|
|---|
Cerebral focal ischemia or sham surgery was performed in male SHR (Taconic Farms, Germantown, NY) or normotensive rats (WKY rats; Charles River, Danvers, Mass) at 16 to 18 weeks of age (weight, 250 to 330 g) by PMCAO, as described in detail previously.1 17 Briefly, the MCA was occluded and cut dorsal to the lateral olfactory tract at the level of the inferior cerebral vein with the use of electrocoagulation (Force 2 Electrosurgical Generator, Valley Lab Inc). In sham-operated rats the dura was opened over the MCA, but the artery was not occluded. Rats were later overdosed with pentobarbital, and forebrains were removed for cortical dissection at various times after PMCAO. The ischemic frontoparietal cortex (ie, the cortex ipsilateral to surgery) was dissected from the ipsilateral hemisphere. The contralateral cortex was dissected as the nonischemic control from the same rat.1 The cortical samples were immediately frozen in liquid nitrogen and stored at -80°C.
Total cellular RNA was prepared from cortical samples as previously described.7 18 As a routine procedure of Northern analysis, RNA samples (40 µg per lane) isolated from cortex at various time points after PMCAO were resolved by electrophoresis, transferred to a nylon membrane, and hybridized to an ELAM-1 cDNA probe (generated by RT-PCR; see below). However, under these conditions no ELAM-1 mRNA signal was detected. Therefore, total cellular RNA was isolated from ischemic and nonischemic cortex of 50 animals at either 2 or 12 hours after PMCAO, and the RNA was subjected to poly(A) RNA isolation with a standard procedure.19 Poly(A) RNA (10 µg per lane) was used for Northern analysis, as described previously.7 20 ELAM-1, ICAM-1,7 c-fos,21 and rpL327 cDNA probes were hybridized to the same membrane sequentially. A probe was stripped from the membrane before rehybridization with the next probe, as described previously.7 20
RT-PCR was used to study the extended temporal expression of ELAM-1 in
the ischemic cortex. Total cellular RNA (5 µg) isolated from
the cortical samples at the indicated time points after PMCAO was
reverse transcribed with 200 U of RNase H- SuperScript II
reverse transcriptase (GIBCO BRL) for 60 minutes at 37°C primed with
1 µg of oligo(dT)12-18 (GIBCO BRL) at conditions
recommended by the manufacturer. The RT products were extracted
with phenol/chloroform, precipitated with ethanol, and the products
were resuspended in 20 µL of a mixture of 10 mmol/L Tris and 1 mmol/L
EDTA (pH 7.5) and stored at -20°C. PCR primers used for
amplification of ELAM-1 and rpL32 were synthesized according to
published sequences (Table
). The rpL32 mRNA expression
has been shown previously to be constant throughout the time course
after PMCAO,7 and therefore it provided an ideal internal
PCR control for normalizing the degree of expression in a quantitative
manner. To ensure that the sensitivity of the amplification was in a
linear range, thus validating the quantitation of signals, we performed
the following control experiments. First, dose-dependent amplification
of the RT-PCR was tested with 0.025, 0.05, 0.1, 0.2, 0.4, 0.8, and 1.6
µg RNA isolated from the rat ischemic cortex at 12 hours
after PMCAO to ensure that the amplification for ELAM-1 and rpL32 mRNAs
was in a linear range. Second, different cycles (15, 20, 25, 30, 35,
and 40 cycles) were compared to identify an optimal number of
amplification cycles for both genes; 25 to 30 PCR cycles were found to
be in the linear portion of the amplification for both genes. Finally,
the optimal amounts of 32P-labeled primers for both genes
were added to adjust the relative signal intensity for the
coamplification. Based on these results, we selected standard
conditions for our experiments as follows: RT products from 0.1
µg RNA, 28 cycles in a total 50 µL reaction mixture containing
1x106 cpm (2 ng) and 6x104 cpm (0.12
ng) 32P-labeled antisense primers for ELAM-1 and rpL32,
respectively, together with 100 ng of each nonradioactive sense and
antisense primer for both genes (Table
). The amplification was
performed with 2.5 U of TaqAmpli polymerase (Perkin-Elmer Cetus) in a
thermocycler (Perkin-Elmer Cetus) according to the conditions described
previously20 : initial denaturation, 3 minutes at 94°C;
initial annealing, 1 minute at 54°C; initial extension, 3 minutes at
72°C. The subsequent 27 cycles were as follows: denaturation, 15
seconds at 94°C; annealing, 20 seconds at 54°C; extension, 1 minute
at 72°C. Ten microliters of the PCR product was electrophoresed
through a 6% native polyacrylamide gel. The gel was dried and
subjected to autoradiography at room temperature.
The identity of the amplified DNA bands for ELAM-1 and rpL32 was
confirmed by Southern blot and/or DNA sequencing, and the DNA fragment
was prepared and used for Northern analysis.
|
PHOSPHORIMAGER (Molecular Dynamics) was used to quantitate the band intensities of the PCR products (or Northern blots), and IMAGEQUANT software version 3.0 (Molecular Dynamics) was used to analyze the results. The relative ELAM-1 mRNA level was determined by the ratio of ELAM-1 to rpL32 signal in each coamplification sample and illustrated the sum of the ratios for the full time course of animals to be 100%.
Statistical evaluation was performed with five complete sets of cortical samples from each time point with the use of one-way ANOVA followed by a post hoc t test. The results are expressed as mean±SE. Significance was accepted for P<.05 by comparing the relative mRNA levels in the ischemic cortex with sham-operated cortex.
| Results |
|---|
|
|
|---|
|
Fig 2
illustrates a representative
autoradiograph of an RT-PCR experiment to detect ELAM-1 mRNA expression
in the focal ischemic and nonischemic cortex and in
sham-operated cortical samples in SHR. The quantitative data for ELAM-1
mRNA (n=5), after normalizing to rpL32 mRNA by calculating the ratios
of ELAM-1 to rpL32 in each sample, are summarized graphically in Fig. 3
. Only a low, basal level of ELAM-1 mRNA was detected
in the sham-operated animals or in the contralateral
(nonischemic) cortex, as well as in the early time points
of the ipsilateral (ischemic) cortical samples. The level of
ELAM-1 mRNA was increased in the ischemic cortex at 6 hours
after PMCAO, reached a peak level at 12 hours (6.9-fold increase
compared with the sham samples; P<.01; n=5), and maintained
an elevated level up to 2 days (3.3-fold increase; P<.01)
after PMCAO (Figs 2
and 3
).
|
|
In addition, the ischemia-induced expression of ELAM-1 mRNA was examined in a normotensive rat strain (WKY rats) 12 hours after PMCAO with the use of quantitative RT-PCR. The results demonstrated a significant upregulation of ELAM-1 mRNA in the ischemic cortex at 12 hours after PMCAO (6.7-fold increase compared with sham-operated samples; P<.01; n=4) in WKY rats (data not shown), which is strikingly similar to that observed in SHR.
| Discussion |
|---|
|
|
|---|
and IL-1ß,14 15 in
the same focal ischemia model. The coordinated expression of
inflammatory cytokines and adhesion molecules before and during
the infiltration of PMNs into ischemic tissue suggests that a
coordinated molecular mechanism initiates and develops the inflammatory
response in focal stroke. For example, the increased expression of
inflammatory cytokines may be responsible for the upregulation
of adhesion molecules including ICAM-1 and ELAM-1, which in turn
contributes to the increased recruitment of leukocytes into the
ischemic tissue and results in increased tissue injury. In
addition, other factors may contribute to the increased expression of
these adhesion molecules after focal brain ischemia. For
example, ICAM-1 upregulation has been recently demonstrated in human
brain microvascular cells in vitro following
reoxygenation after exposure to low oxygen
tensions.24 However, the relation of the degree of ELAM-1
protein levels to the degree of the mRNA expression induced by focal
ischemia remains to be further examined when antibodies against
rat ELAM-1 become available. Also, the cellular sources of ELAM-1
expression in the ischemic cortex also need to be confirmed,
although in previous studies the expression of this molecule has been
found exclusively on vascular endothelial
cells.5 6 12 ELAM-1 mRNA appears to be a rare message upregulated in focal cerebral ischemia, as we failed to detect any signal using standard Northern blot methodology (40 µg total RNA per lane). We were able to successfully detect ELAM-1 mRNA by using either a large amount of RNA for Northern blot [10 µg poly(A) RNA per lane] or the highly sensitive quantitative RT-PCR method. The relatively rare message of ELAM-1 may reflect a limited cellular source for this gene expression (ie, the vascular endothelium). In addition to the techniques used in this report, other methods such as ribonuclease protection assay or nuclear run-on analysis may also be useful to detect rare messages. Comparatively, RT-PCRbased quantitation appears to be more attractive because of its sensitivity and simplicity and the lower amount of RNA required. In addition to the quantitative RT-PCR method described in this report and introduced previously by Chelly et al,25 which uses a housekeeping gene as an internal control for the coamplification, a "mimic" PCR technique can also be used.26 27 When all these techniques used for the detection of mRNA levels are compared, however, Northern blot analysis should be the first choice, since it is simple, reliable, and directly assesses the amount of message present.
In conclusion, the present data demonstrated a kinetic induction profile for ELAM-1 mRNA in the ischemic cortex after focal ischemia. The data are consistent with the possibility that ELAM-1 is expressed and plays a role in the inflammatory response to cerebral ischemic tissue injury.
| Selected Abbreviations and Acronyms |
|---|
|
| Acknowledgments |
|---|
Received December 8, 1994; revision received May 23, 1995; accepted May 25, 1995.
| References |
|---|
|
|
|---|
2. Clark RK, Lee EV, Fish CJ, White RF, Price WJ, Jonak ZL, Feuerstein GZ, Barone FC. Development of tissue damage, inflammation and resolution following stroke: an immunohistochemical and quantitative planimetric study. Brain Res Bull. 1993;31:565-572. [Medline] [Order article via Infotrieve]
3. Garcia JH, Liu KF, Yoshida Y, Lian J, Chen S, del Zoppo GJ. Influx of leukocytes and platelets in an evolving brain infarct (Wistar rat). Am J Pathol. 1994;144:188-199. [Abstract]
4.
Hallenbeck JM, Dutka AJ, Tanishima T, Kochanek
PM, Kumaroo KK, Thompson CB, Obrenovitch TP, Contreras TJ.
Polymorphonuclear leukocyte accumulation in brain region
with low blood flow during the early postischemic
period. Stroke. 1986;17:246-253.
5. Beekhuizen H, van Furth R. Monocyte adherence to human vascular endothelium. J Leukocyte Biol. 1993;54:363-378. [Abstract]
6. Thornhill MH, Haskard DO. Leukocyte adhesion to endothelium. In: Hortton MA, ed. Blood Cell Biochemistry: Macrophages and Related Cells. New York, NY: Plenum Publishing Corp; 1993;5:371-392.
7. Wang XK, Siren A-L, Liu Y, Yue T-L, Barone FC, Feuerstein GZ. Upregulation of intercellular adhesion molecule 1 (ICAM-1) on brain microvascular endothelial cells in rat ischemic cortex. Mol Brain Res. 1994;26:61-68. [Medline] [Order article via Infotrieve]
8. Okada Y, Copeland BR, Mori E, Tung M-M, Thomas WS, del Zoppo GJ. P-selectin and intercellular adhesion molecule-1 expression after focal brain ischemia and reperfusion. Stroke. 1994;25:202-211. [Abstract]
9. Clark WM, Madden KP, Rothlein R, Zivin JA. Reduction of central nervous system ischemic injury by monoclonal antibody to intercellular adhesion molecule. J Neurosurg. 1991;75:623-627. [Medline] [Order article via Infotrieve]
10. Bowes WP, Zivin JA, Rothlein R. Monoclonal antibody to the ICAM-1 adhesion site reduces neurological damage in a rabbit cerebral embolism stroke model. Exp Neurol. 1993;119:215-219. [Medline] [Order article via Infotrieve]
11.
Zhang RL, Chopp M, Li Y, Zaloga C, Jiang N, Jones M,
Miyasaka M, Ward P. Anti-ICAM-1 antibody reduces
ischemic cell damage after transient middle cerebral artery
occlusion in the rat. Neurology. 1994;44:1747-1751.
12.
Bevilacqua MP, Pober JS, Mendrick DL, Cotran RS,
Gimbrone MA Jr. Identification of an inducible
endothelial-leukocyte adhesion molecule.
Proc Natl Acad Sci U S A. 1987;84:9238-9242.
13. Granger DN, Kubes P. The microcirculation and inflammation of leukocyte-endothelial cell adhesion. J Leukoc Biol. 1994;55:662-675. [Abstract]
14.
Liu T, Clark RK, McDonnell PC, Young PR, White RF,
Barone FC, Feuerstein GZ. Tumor necrosis factor-
expression
in ischemic neurons. Stroke. 1994;25:1481-1488. [Abstract]
15.
Liu T, McDonnell PC, Young PR, White RF, Siren AL,
Hallenbeck JM, Barone FC, Feuerstein GZ. Interleukin-1ß mRNA
expression in ischemic rat cortex. Stroke. 1993;24:1746-1751.
16.
Wang XK, Yue T-L, Barone FR, White RF, Feuerstein GZ.
Concomitant cortical expression of TNF-
and IL-1ß mRNAs
follows early response gene expression in transient focal
ischemia. Mol Chem Neuropathol. 1994;23:103-114. [Medline]
[Order article via Infotrieve]
17. Barone FC, Price WJ, White RF, Willette RN, Feuerstein GZ. Genetic hypertension and increased susceptibility to cerebral ischemia. Neurosci Biobehav Rev. 1992;16:219-233. [Medline] [Order article via Infotrieve]
18. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156-159. [Medline] [Order article via Infotrieve]
19. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1989.
20.
Wang XK, Lee G, Liebhaber SA, Cooke NE. Human
cysteine-rich protein: a member of the LIM/double-finger family
displaying coordinate serum induction with c-myc.
J Biol Chem. 1992;267:9176-9184.
21. Wang XK, Yue T-L, Young PR, Barone FR, Feuerstein GZ. Expression of interleukin-6, c-fos and zif268 mRNAs in rat ischemic cortex. J Cereb Blood Flow Metab. 1995;15:166-171. [Medline] [Order article via Infotrieve]
22. Fries JW, Williams AJ, Atkins RC, Newman W, Lipscomb MF, Collins T. Expression of VCAM-1 and E-selectin in an in vivo model of endothelial activation. Am J Pathol. 1993;143:725-737. [Abstract]
23.
Rajchel A, Chan Y-L, Wool IG. The primary
structure of rat ribosomal protein L32. Nucleic Acids
Res. 1988;16:2347.
24. Hess DC, Zhao W, Carroll J, McEachin M, Buchanan K. Increased expression of ICAM-1 during reoxygenation in brain endothelial cells. Stroke. 1994;25:1463-1468. [Abstract]
25. Chelly J, Kaplan JC, Maire P, Gautron S, Kahn A. Transcription of the dystrophin gene in human muscle and non-muscle tissues. Nature. 1988;333:858-860. [Medline] [Order article via Infotrieve]
26.
Wang AM, Doyle MV, Mark DV. Quantitation of mRNA
by the polymerase chain reaction. Proc Natl Acad Sci
U S A. 1989;86:9717-9721.
27.
Li B, Sehajpal PK, Khanna A, Vlassara H, Cerami A,
Stenzel KH, Suthanthiran M. Differential regulation of
transforming growth factor ß and interleukin 2 genes in human T
cells: demonstration by usage of novel competitor DNA constructs in the
quantitative polymerase chain reaction. J Exp
Med. 1991;174:1259-1262.
This article has been cited by other articles:
![]() |
C.J.M. Frijns and L.J. Kappelle Inflammatory Cell Adhesion Molecules in Ischemic Cerebrovascular Disease Stroke, August 1, 2002; 33(8): 2115 - 2122. [Abstract] [Full Text] [PDF] |
||||
![]() |
J J Nissen, D Mantle, B Gregson, and A D Mendelow Serum concentration of adhesion molecules in patients with delayed ischaemic neurological deficit after aneurysmal subarachnoid haemorrhage: the immunoglobulin and selectin superfamilies J. Neurol. Neurosurg. Psychiatry, September 1, 2001; 71(3): 329 - 333. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Y. WONG, N. J. LAPING, L. C. CONTINO, B. A. OLSON, E. GRYGIELKO, and D. P. BROOKS Gene expression in rats with renal disease treated with the angiotensin II receptor antagonist, eprosartan Physiol Genomics, November 9, 2000; 4(1): 35 - 42. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. KUMAR, D. P. BROOKS, B. A. OLSON, and N. J. LAPING Sgk, a Putative Serine/Threonine Kinase, Is Differentially Expressed in the Kidney of Diabetic Mice and Humans J. Am. Soc. Nephrol., December 1, 1999; 10(12): 2488 - 2494. [Abstract] [Full Text] |
||||
![]() |
A. Kimura, M. Ohmichi, H. Kurachi, H. Ikegami, J. Hayakawa, K. Tasaka, Y. Kanda, Y. Nishio, H. Jikihara, N. Matsuura, et al. Role of Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase Cascade in Gonadotropin-releasing Hormone-induced Growth Inhibition of a Human Ovarian Cancer Cell Line Cancer Res., October 1, 1999; 59(20): 5133 - 5142. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Iadecola, C. A. Salkowski, F. Zhang, T. Aber, M. Nagayama, S. N. Vogel, and M. Elizabeth Ross The Transcription Factor Interferon Regulatory Factor 1 Is Expressed after Cerebral Ischemia and Contributes to Ischemic Brain Injury J. Exp. Med., February 15, 1999; 189(4): 719 - 727. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Bitsch, W. Klene, L. Murtada, H. Prange, and P. Rieckmann A Longitudinal Prospective Study of Soluble Adhesion Molecules in Acute Stroke Stroke, October 1, 1998; 29(10): 2129 - 2135. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Pantoni, C. Sarti, and D. Inzitari Cytokines and Cell Adhesion Molecules in Cerebral Ischemia : Experimental Bases and Therapeutic Perspectives Arterioscler. Thromb. Vasc. Biol., April 1, 1998; 18(4): 503 - 513. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.J.M. Frijns, L.J. Kappelle, J. v. Gijn, H.K. Nieuwenhuis, J.J. Sixma, and R. Fijnheer Soluble Adhesion Molecules Reflect Endothelial Cell Activation in Ischemic Stroke and in Carotid Atherosclerosis Stroke, November 1, 1997; 28(11): 2214 - 2218. [Abstract] [Full Text] |
||||
![]() |
X. Wang, F. C. Barone, N. V. Aiyar, G. Z. Feuerstein, and G. J. del Zoppo Interleukin-1 Receptor and Receptor Antagonist Gene Expression After Focal Stroke in Rats Stroke, January 1, 1997; 28(1): 155 - 162. [Abstract] [Full Text] |
||||
![]() |
X. Wang, C. Louden, E. H. Ohlstein, J. M. Stadel, J.-L. Gu, and T.-L. Yue Osteopontin Expression in Platelet-Derived Growth Factor–Stimulated Vascular Smooth Muscle Cells and Carotid Artery After Balloon Angioplasty Arterioscler. Thromb. Vasc. Biol., November 1, 1996; 16(11): 1365 - 1372. [Abstract] [Full Text] |
||||
![]() |
X. Wang, T.-L. Yue, E. H. Ohlstein, C.-P. Sung, and G. Z. Feuerstein Interferon-inducible Protein-10 Involves Vascular Smooth Muscle Cell Migration, Proliferation, and Inflammatory Response J. Biol. Chem., September 27, 1996; 271(39): 24286 - 24293. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Kim, S. S. Yoon, Y. H. Kim, and J. S. Ryu Serial Measurement of Interleukin-6, Transforming Growth Factor-ß, and S-100 Protein in Patients With Acute Stroke Stroke, September 1, 1996; 27(9): 1553 - 1557. [Abstract] [Full Text] |
||||
![]() |
H.-P. Haring, E. L. Berg, N. Tsurushita, M. Tagaya, G. J. del Zoppo, and M. J Eppihimer E-Selectin Appears in Nonischemic Tissue During Experimental Focal Cerebral Ischemia Stroke, August 1, 1996; 27(8): 1386 - 1392. [Abstract] [Full Text] |
||||
![]() |
X. Wang, S. A. Douglas, C. Louden, L. M. Vickery-Clark, G. Z. Feuerstein, and E. H. Ohlstein Expression of Endothelin-1, Endothelin-3, Endothelin-Converting Enzyme-1, and Endothelin-A and Endothelin-B Receptor mRNA After Angioplasty-Induced Neointimal Formation in the Rat Circ. Res., February 1, 1996; 78(2): 322 - 328. [Abstract] [Full Text] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1995 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |